Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

被引：32
|
作者：
van der Helm, L. H. [1 ]
Veeger, N. J. G. M. [1 ]
van Marwijk Kooy, M. [2 ]
Beeker, A. [3 ]
de Weerdt, O. [4 ]
de Groot, M. [5 ]
Alhan, C. [6 ]
Hoogendoorn, M. [7 ]
Laterveer, L. [8 ]
van de Loosdrecht, A. A. [6 ]
Koedam, J. [9 ]
Vellenga, E. [1 ]
Huls, G. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9713 GZ Groningen, Netherlands
[2] Isala Klin, Dept Internal Med, Zwolle, Netherlands
[3] Spaarne Ziekenhuis, Dept Internal Med, Hoofddorp, Netherlands
[4] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands
[5] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands
[6] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands
[7] Med Ctr Leeuwarden, Dept Hematol, Leeuwarden, Netherlands
[8] Diaconessenhuis, Dept Internal Med, Meppel, Netherlands
[9] Celgene BV, Utrecht, Netherlands
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷 / 08期
关键词：
Acute myeloid leukemia; Older age; Azacitidine; Bone marrow blast count; Predictors; ACUTE MYELOID-LEUKEMIA; INTERNATIONAL WORKING GROUP; CONVENTIONAL CARE REGIMENS; ELDERLY-PATIENTS; MYELODYSPLASTIC SYNDROMES; RESPONSE CRITERIA; OLDER PATIENTS; PHASE-III; AGE; CLASSIFICATION;
D O I：
10.1016/j.leukres.2013.03.022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with >= 30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML, performance score >= 2, and white blood cell count >= 15x10(9)/L as independent adverse predictors for OS. The BM blast percentage, however, had no impact on OS (P=0.55). In conclusion, administration of azacitidine is effective in AML patients with 20-30% and >30% BM blasts. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：877 / 882
页数：6
相关论文
共 50 条
  • [1] Acute myeloid Leukemia (AML) Azacitidine improves Overall Survival of elderly Patients with more than 30% Bone Marrow Blasts
    Schoellmann, Claudia
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 311 - 311
  • [2] Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study
    Doehner, Hartmut
    Seymour, John F.
    Butrym, Aleksandra
    Wierzbowska, Agnieszka
    Selleslag, Dominik
    Lang, Jun Ho
    Cavenagh, James D.
    Kumar, Rajat
    Schuh, Andre C.
    Candoni, Anna
    Recher, Christian
    Sandhu, Irwindeep
    Bernal del Castillo, Teresa
    Al-Ali, Haifa Kathrin
    Martinelli, Giovanni
    Falantes, Jose
    Stone, Richard M.
    Minden, Mark D.
    McIntyre, Heidi
    Songer, Stephen
    Lucy, Lela M.
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2014, 124 (21)
  • [3] OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH > 30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY
    Doehner, H.
    Seymour, J. F.
    Butrym, A.
    Wierzbowska, A.
    Selleslag, D.
    Jang, J. H.
    Cavenagh, J. D.
    Kumar, R.
    Schuh, A. C.
    Candoni, A.
    Recher, C.
    Sandhu, I.
    Bernal del Castillo, T.
    Al-Ali, H. K.
    Martinelli, G.
    Falantes, J.
    Nopenney, R.
    Stone, R. M.
    Minden, M. D.
    McIntyre, H.
    Songer, S.
    Lucy, L. M.
    Beach, C. L.
    Dombret, H.
    LEUKEMIA RESEARCH, 2015, 39 : S48 - S49
  • [4] International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
    Dombret, Herve
    Seymour, John F.
    Butrym, Aleksandra
    Wierzbowska, Agnieszka
    Selleslag, Dominik
    Jang, Jun Ho
    Kumar, Rajat
    Cavenagh, James
    Schuh, Andre C.
    Candoni, Anna
    Recher, Christian
    Sandhu, Irwindeep
    Bernal del Castillo, Teresa
    Al-Ali, Haifa Kathrin
    Martinelli, Giovanni
    Falantes, Jose
    Noppeney, Richard
    Stone, Richard M.
    Minden, Mark D.
    McIntyre, Heidi
    Songer, Steve
    Lucy, Lela M.
    Beach, C. L.
    Doehner, Hartmut
    BLOOD, 2015, 126 (03) : 291 - 299
  • [5] AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY
    Seymour, J. F.
    Doehner, H.
    Butrym, A.
    Wierzbowska, A.
    Selleslag, D.
    Jang, J. H.
    Cavenagh, J. D.
    Kumar, R.
    Schuh, A. C.
    Candoni, A.
    Recher, C.
    Sandhu, I.
    del Castillo, T. Bernal
    Al-Ali, H. K.
    Martinelli, G.
    Falantes, J.
    Nopenney, R.
    Stone, R. M.
    Minden, M. D.
    McIntyre, H.
    Songer, S.
    Lucy, L. M.
    Beach, C. L.
    Dombret, H.
    LEUKEMIA RESEARCH, 2015, 39 : S63 - S64
  • [6] Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial
    Seymour, John F.
    Doehner, Hartmut
    Butrym, Aleksandra
    Wierzbowska, Agnieszka
    Selleslag, Dominik
    Jang, Jun Ho
    Cavenagh, James D.
    Kumar, Rajat
    Schuh, Andre C.
    Candoni, Anna
    Recher, Christian
    Sandhu, Irwindeep
    Bernal del Castillo, Teresa
    Al-Ali, Haifa Kathrin
    Martinelli, Giovanni
    Falantes, Jose
    Stone, Richard M.
    Minden, Mark D.
    McIntyre, Heidi
    Songer, Stephen
    Lucy, Lela M.
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2014, 124 (21)
  • [7] AZACITIDINE (AZA) VS. CONVENTIONAL TREATMENT REGIMENS (CTR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (>30% BONE MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: A SUBGROUP ANALYSIS OF AZA-AML-001
    Bernal, T.
    Dombret, H.
    Doehner, H.
    Lucy Lela, M.
    Beach, C. L.
    McCallum, P.
    HAEMATOLOGICA, 2015, 100 : 134 - 135
  • [8] Circulating Tumor DNA: Less Invasive, More Representative Method to Unveil the Genomic Landscape of Newly Diagnosed Multiple Myeloma Than Bone Marrow Aspirates
    Liu, Yang
    Guo, Jiapei
    Yi, Yuting
    Gao, Xuan
    Wen, Lei
    Duan, Wenbing
    Wen, Zhaohong
    Liu, Yaoyao
    Guan, Yanfang
    Xia, Xuefeng
    Ma, Ling
    Fu, Rong
    Liu, Lihong
    Huang, Xiaojun
    Ge, Qing
    Lu, Jin
    CANCERS, 2022, 14 (19)
  • [9] Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
    Tikhonova, Irina A.
    Hoyle, Martin W.
    Snowsill, Tristan M.
    Cooper, Chris
    Varley-Campbell, Joanna L.
    Rudin, Claudius E.
    Mota, Ruben E. Mujica
    PHARMACOECONOMICS, 2017, 35 (03) : 363 - 373
  • [10] Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
    Irina A. Tikhonova
    Martin W. Hoyle
    Tristan M. Snowsill
    Chris Cooper
    Joanna L. Varley-Campbell
    Claudius E. Rudin
    Ruben E. Mujica Mota
    PharmacoEconomics, 2017, 35 : 363 - 373
12345